CoChat
Sign Up
Cited by 759Pharmacology and Obesity TreatmentBariatric Surgery and OutcomesEating Disorders and Behaviors

Executive Summary

Open access
·1998·Obesity Research
DOI 10.1002/j.1550-8528.1998.tb00690.x
Open this paper in CoChat — free accountOpen PDF

Abstract

As of September 1997, the Food and Drug Administration (FDA) requested the voluntary withdrawal from the market of dexfenfturarnine and fenfturamine due to a reported association between valvular disease and the use of dexfenfturamine or fenfturamine alone or combined with phentermine.The use of these drugs for weight reduction, therefore, is not recommended in this report.Sibutramine is approved by FDA for long-term use.It has limited but definite effects on weight loss and can facilitate weight loss maintenance.(Note: FDA approval for orlistat is pending a resolution of labeling issues and results of Phase III trials.)

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/j.1550-8528.1998.tb00690.x

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Short-term studies show numerous benefits of weight loss, including improvements in glycemic control, cardiovascular disease risk factors, quality of life, and other obesity-related comorbidities.

    “This recommendation is based on short-term studies showing numerous benefits of weight loss, including improvements in glycemic control, cardiovascular disease risk factors, quality of life and other obesity-related comorbidities.2”

    From Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes (2013) · cites this paper as [2]

    The Evidence-Based Guidelines and Blood Glucose sections (p. 58S) report improvements in cardiovascular risk factors and blood glucose with weight loss; the diabetes discussion (p. 90S) also reports improved glycemic control. The Surgery section reports improvements in obesity-related comorbidities, but says only that obesity impairs quality of life—not that short-term weight-loss studies found quality-of-life improvements. (LLM, conf=0.86)

    Experimental — accuracy not yet measured

  • ATP III cutpoints for abdominal obesity came from the 1998 NIH obesity clinical guidelines: waist circumference at least 102 cm for men and at least 88 cm for women.

    “Its cutpoints for abdominal obesity came from the definition in the 1998 National Institutes of Health obesity clinical guidelines 108 ; they were a waist circumference of Ն102 cm (Ն40 in) for men and Ն88 cm (Ն35 in) for women.”

    From Diagnosis and Management of the Metabolic Syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement (2005) · cites this paper as [108]

  • Weight reduction and keeping a lower weight are best accomplished through reduced calorie intake, more physical activity, and behavior-change principles.

    “Both weight reduction and maintenance of a lower weight are best achieved by a combination of reduced caloric intake and increased physical activity and the use of principles of behavior change.”

    From Diagnosis and Management of the Metabolic Syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement (2005) · cites this paper as [108]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cited by

Sorted by citations

Related

Venue
Obesity Research
Publisher
Wiley
Published
1998-09
Volume
6
Issue
S2
ISSN
  • 1071-7323 (ISSN-L)
  • 1550-8528
DOI
10.1002/j.1550-8528.1998.tb00690.x
OpenAlex
W4246016694
Cited by
758
References
0
Citations by year
2026: 9 · 2025: 6 · 2024: 11 · 2023: 11 · 2022: 15 · 2021: 14 · 2020: 14 · 2019: 19 · 2018: 16 · 2017: 23 · 2016: 32 · 2015: 36 · 2014: 50 · 2013: 45 · 2012: 42
FWCI
10.98
Type
journal article
Language
en
Open access
Licence
onlinelibrary.wiley.com/termsAndConditions#vor (vor, 5119 d)
Locations
Obesity Research (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
  • Social Sciences › Psychology › Clinical Psychology › Eating Disorders and Behaviors
Keywords
dexfenfluramine, fenfluramine, valvular heart disease, phentermine, sibutramine, orlistat, weight loss, weight loss maintenance, obesity pharmacotherapy, drug safety

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review